Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

OpGen, Thermo Fisher supply agreement , 7/17

July 2017—OpGen has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help health care providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.

Infectious diseases monoclonal antibodies, 7/17

July 2017—The Binding Site’s Immunologicals Group has completed a major expansion to its monoclonal antibody product offerings. In addition to the company’s conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, a number of monoclonal antibodies focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma have been introduced.

Inventory management software, 7/17

October 2017—InvMan, an inventory management software solution from Cove Laboratory Software, automates inventory management by providing direct scanning of vendor reagent barcode labels. Using a portable scanner, the vendor 1-D or 2-D barcode is scanned and uploaded to the reagent database in InvMan.

BioFire unveils Salt Lake City facility, 7/17

July 2017—BioMérieux announced that BioFire Diagnostics, its molecular biology affiliate, celebrated the opening of its Alain Mérieux Center for Molecular Diagnostics facility in Salt Lake City. The facility, home to more than 1,000 employees, is dedicated to the development of FilmArray, BioFire’s molecular PCR multiplex system for the syndromic diagnosis of infectious diseases.

Lung, colon cancer research panels, 7/17

July 2017—Agena Bioscience introduced targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSeek Lung and Colon Panels enable the detection of mutations as low as 0.1 percent minor allele frequency from circulating tumor cells and circulating tumor DNA. The iPlex HS Lung and Colon Panels enable detection of mutations as low as one percent MAF from solid tumor tissue.

von Willebrand factor activity test, 7/17

July 2017—BloodCenter of Wisconsin launched its VWF GPIbM Activity assay, which aims to more accurately measure von Willebrand factor activity. The assay detects qualitative VWF defects, reducing variability and providing more precise, reliable, and sensitive test results.

NMDX acquires Nuclea, offers HER2/neu tests, 7/17

July 2017—NanoMolecularDX announced it has acquired the assets of Nuclea Biotechnologies. Assets include all of the intellectual property, biological material, capital equipment, licenses, FDA approvals and allowances, marketing and customer materials, trademarks, and all relevant scientific data. NMDX began selling in May HER2/neu blood testing kits acquired from Nuclea.

Forensic DNA grade consumables, 7/17

July 2017—Eppendorf introduced its Eppendorf Forensic DNA Grade product line, which complies with the requirements of ISO 18385. This standard specifies requirements for the production of products used in the collection, storage, and analysis of biological material for forensic DNA purposes.

Multiplex immunohistochemistry kit, 7/17

July 2017—Enzo Life Sciences unveiled its Multiview Plus (mouse-HRP/rabbit-AP) IHC Kit (brown/green). This nonbiotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed, paraffin-embedded tissues. The kit optimizes the IHC process by including the entire workflow, from antigen retrieval to visualization.

Study of clinical utility of prostate cancer test, 7/17

July 2017—MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association annual meeting in Boston.

MARKETPLACE

TRENDING